menu
    • menu

    Company profile for Viyash Life Sciences

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, APIs and advanced intermediates Viyash and its subsidiaries operate 10 API / Intermediate facilities with a combined capacity ~2000 KL and diversified capabilities in every aspect - small / large volume, potent / non-potent, regulated / semi-regulate...
    Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, APIs and advanced intermediates Viyash and its subsidiaries operate 10 API / Intermediate facilities with a combined capacity ~2000 KL and diversified capabilities in every aspect - small / large volume, potent / non-potent, regulated / semi-regulated markets. In addition, we also operate one formulation manufacturing facility in New Jersey, USA with a capacity of ~ 1.2 Bn units.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Viyash Life Sciencesindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderab...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.viyash.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/viyash-life-sciences-pvt-ltd/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI South East Asia

    Not Confirmed

    envelop Contact Supplier

    CPhI South East Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 1235

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaProviding RSMs & API to Global Pharma CompaniesProviding RSMs & API to Global Pharma Companies

    Providing RSMs & API to Global Pharma Companies
    Providing RSMs & API to Global Pharma Companies

    reelProviding RSMs & API to Global Pharma Companies

    This PharmaReel showcases Allsino Pharmaceutical, a company that provides GMP-certified RSMs and APIs to global pharma companies, specializing in peptides, oligonucleotides, and small molecule CDMO services. Allsino has a presence in the US, EU, China and Japan.

    Impressions: 1215

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    The pharmaceutical industry has witnessed a wave of mergers, acquisitions, and strategic partnerships so far in the first half (H1) of 2025, with deal values exceeding US$ 170 billion.PharmaCompass’ data shows oncology alone accounted for nearly US$ 47 billion in deal value, followed by US$ 18 billion each in immunology and psychiatry, US$ 17 billion in nutrition/weight loss and US$ 7 billion in neurology.Pharma majors such as Johnson & Johnson and Bristol Myers Squibb led with two deals worth over US$ 10 billion each. Sanofi executed a series of deals in the immunology and neuro-inflammation space. And Eli Lilly stood out for its aggressive dealmaking, which spanned oncology, pain, RNA therapies, and AI-driven oligonucleotides. In all, it signed seven deals worth over US$ 1 billion each. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available)H1 records several mega deals as J&J buys Intra-Cellular, BMS ties up with BioNTech, Sanofi acquires BlueprintJohnson & Johnson dominated headlines with its US$ 14.6 billion acquisition of Intra-Cellular Therapies in January 2025. This marks the largest biopharma deal since Novo Nordisk’s US$ 16.5 billion acquisition of Catalent in February 2024. This acquisition positions J&J as a formidable player in the neuroscience space. Bristol Myers Squibb entered into a US$ 11.1 billion partnership with BioNTech. The deal structure — US$ 3.5 billion in unconditional payments and up to US$ 7.6 billion in milestone payments — demonstrates BMS’ confidence in BNT327, a next-generation bispecific antibody in phase 3 trials for treating extensive stage small cell lung cancer and non-small cell lung cancer.Sanofi acquired Blueprint Medicines for US$ 9.5 billion in order to enhance its rare disease portfolio. The French drugmaker is also creating a comprehensive immunology portfolio. The company signed a US$ 1.9 billion deal for Dren Bio’s DR-0201 bispecific antibody for autoimmune diseases. Sanofi also acquired Vigil Neuroscience for US$ 470 million for its phase 2-ready Alzheimer’s disease candidate. Additionally, the drugmaker secured a US$ 1.84 billion global license agreement with Earendil Labs for two next-generation bispecific antibodies.Pfizer’s US$ 6.05 billion partnership with 3SBio provides it global licensing rights (excluding China) for SSGJ-707, a bispecific antibody currently undergoing multiple clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Obesity gold rush sees Roche, AbbVie, Sciwind ink deals; Novo pledges over US$ 5 bn across three dealsThe obesity therapeutics market has triggered intense competition among pharmaceutical giants. Roche’s US$ 5.3 billion partnership with Zealand Pharma is focused on petrelintide, an amylin analog designed to preserve lean mass better than existing GLP-1-based treatments. The collaboration combines petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388, creating a differentiated obesity treatment.Market leader Novo Nordisk has promised over US$ 5 billion across three major obesity deals in 2025. The US$ 2.2 billion Septerna collaboration targets oral small molecule medicines for obesity and cardiometabolic diseases.Novo signed a separate US$ 2 billion agreement with China’s United Biotechnology for UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors in phase 2 clinical development for obesity, type 2 diabetes, and other diseases. The company’s third major deal, a US$ 1 billion partnership with Lexicon Pharmaceuticals, provides it access to LX9851, a molecule in preclinical development for obesity and associated metabolic disorders.Sciwind Biosciences secured a US$ 2.5 billion global licensing and collaboration agreement with Verdiva Bio Limited for the global development and commercialization of a portfolio of metabolic diseases therapies. AbbVie entered the amylin arena through its US$ 2.2 billion Gubra partnership for GUB014295, a candidate in phase 1 trials for treating obesity. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Molecular glue degraders draw investments; Lilly signs seven deals over US$ 1 billion eachMolecular glue degraders have emerged as a transformative therapeutic modality, attracting significant investment across multiple partnerships. AbbVie’s US$ 1.64 billion collaboration with Neomorph leverages the biotech’s leading molecular glue discovery platform for oncology and immunology applications.Genentech’s potential US$ 2.1 billion partnership with Orionis Biosciences focuses on small-molecule monovalent glue medicines for novel and challenging oncology targets. This is the second partnership between the two companies, following their initial 2023 collaboration.Eli Lilly has collaborated with Magnet Biomedicine, utilizing Magnet’s TrueGlue discovery platform for oncology applications. The deal could be worth up to US$ 1.3 billion.Eli Lilly has emerged as one of 2025’s most active dealmakers, with approximately seven deals exceeding US$ 1 billion each. The company’s US$ 2.5 billion Scorpion Therapeutics acquisition provides access to STX-478, an experimental oral therapy in early-stage trials for breast cancer and advanced solid tumors, potentially addressing 30 to 40 percent of hormone-positive breast cancer patients.On June 17, Lilly announced the acquisition of gene-editing startup Verve Therapeutics for US$ 1.3 billion. Lilly’s US$ 1 billion SiteOne acquisition announced in May brings STC-004, a phase 2-ready non-opioid chronic pain treatment to its pipeline. Other partnerships announced by Lilly include a US$ 1.4 billion capsid licensing deal with Sangamo for central nervous system disease genomic medicines and a US$ 1.3 billion collaboration with South Korean company Rznomics for RNA-based hearing loss treatments. Lilly has also strengthened its oligonucleotide pipeline through a potential US$ 1 billion collaboration with Creyon Bio for AI-designed oligonucleotide therapies targeting RNA. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Merck KGaA acquires SpringWorks for US$ 3.9 bn; Novartis buys out Anthos for US$ 3.1 bnAstraZeneca signed a US$ 5.3 billion AI-led research agreement with China’s CSPC Pharmaceuticals Group to advance the discovery of novel oral candidates for immunological diseases. Merck KGaA acquired SpringWorks for US$ 3.9 billion in April, which gave it access to two FDA-approved therapies — Ogsiveo (nirogacestat), the first and only approved therapy for adult patients with progressing desmoid tumors requiring systemic treatment, and Gomekli (mirdametinib), the first and only FDA-approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.Novartis’ US$ 3.1 billion Anthos Therapeutics acquisition centered around abelacimab, a potential first-in-class monoclonal antibody currently in three phase 3 studies for stroke and systemic embolism prevention in atrial fibrillation patients.GSK’s US$ 2 billion acquisition of Boston Pharmaceuticals’ efimosfermin targets steatotic liver disease (fatty liver disease). The medicine is also in clinical development for MASH treatment. GSK’s second major deal involved the US$ 1.15 billion acquisition of US biotech IDRx, strengthening its gastrointestinal cancer portfolio.The pharma industry also drew some private equity interest as Bain Capital acquired Japan’s Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group for US$ 3.3 billion. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Our viewDespite an uncertain geopolitical environment, the year has seen a surge in M&As and dealmaking in the first half of 2025. However, a sizable chunk of the acquisitions were bolt-on transactions, indicating that companies are not ready to take on risks, and are buying out smaller players who strategically fit into their operations. Going forward, there are indications that M&A activity will stay strong throughout 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2783

    https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025

    #PharmaFlow by PHARMACOMPASS
    19 Jun 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    SeQuent Viyash merger approved by stock exchange; NCLT filing on
    SeQuent Viyash merger approved by stock exchange; NCLT filing on

    02 Jun 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/sequentviyash-merger-receives-stock-exchange-approvals-nclt-filing-underway-17233

    INDPHARMAPOST
    02 Jun 2025
    Share Share
    CCI clears merger of nine pharma entities with Sequent Scientific
    CCI clears merger of nine pharma entities with Sequent Scientific

    21 Jan 2025

    // BUSINESS STD

    https://www.business-standard.com/companies/news/cci-clears-merger-of-nine-pharma-entities-with-sequent-scientific-125012101524_1.html

    BUSINESS STD
    21 Jan 2025
    Share Share
    Sequent Scientific, Viyash Life announce Rs 8,000 crore merger
    Sequent Scientific, Viyash Life announce Rs 8,000 crore merger

    28 Sep 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sequent-scientific-viyash-life-sciences-announce-rs-8000-crore-merger/articleshow/113720326.cms

    ECONOMICTIMES
    28 Sep 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Bilastine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Bilastine

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38966

    Submission : 2023-10-09

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 307MF10015

    Registrant's Address : 8-2-293/174/3, Beside BN Reddy colony, Road No. 14, Banjara Hills, Hyderabad-500 034, Telangana, INDIA.

    Initial Date of Registration : 2025-01-23

    Latest Date of Registration :

    EU-WCarrow-down
    ✖

    Date of Issue : 2022-10-17

    Valid Till : 2025-08-08

    Written Confirmation Number : WC-0382

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0213

    Start Marketing Date : 2024-06-28

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brimonidine Tartrate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Brimonidine Tartrate

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 22230

    Submission : 2008-12-01

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2018-124 - Rev 00

    Issue Date : 2020-05-14

    Type : Chemical

    Substance Number : 2760

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-11-28

    Valid Till : 2025-09-08

    Written Confirmation Number : WC-0072

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0110

    Start Marketing Date : 2013-08-23

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Deferasirox

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Deferasirox

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-12-30

    Pay. Date : 2019-12-16

    DMF Number : 31877

    Submission : 2019-11-20

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2021-038 - Rev 00

    Issue Date : 2023-07-07

    Type : Chemical

    Substance Number : 2933

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-10-21

    Valid Till : 2025-09-11

    Written Confirmation Number : WC-0451

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0301

    Start Marketing Date : 2017-05-18

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Hydroxyzine Dihydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Hydroxyzine Dihydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-11-18

    Pay. Date : 2016-10-24

    DMF Number : 19596

    Submission : 2006-07-12

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2015-186 - Rev 00

    Issue Date : 2021-07-12

    Type : Chemical

    Substance Number : 916

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-10-21

    Valid Till : 2025-09-11

    Written Confirmation Number : WC-0451

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0303

    Start Marketing Date : 1982-01-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Ketorolac Trometamol

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Ketorolac Trometamol

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-03-03

    Pay. Date : 2013-03-04

    DMF Number : 26870

    Submission : 2013-02-07

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2015-046 - Rev 00

    Issue Date : 2021-06-04

    Type : Chemical

    Substance Number : 1755

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-11-28

    Valid Till : 2025-09-08

    Written Confirmation Number : WC-0072

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0117

    Start Marketing Date : 1992-11-09

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : IMCD Korea Co., Ltd.

    Registration Date : 2021-05-14

    Registration Number : 20200227-61-C-384-14(1)

    Manufacturer Name : Symed Labs Limited(Unit II) @Symed Labs Limited(Unit VI)

    Manufacturer Address : Plot-25/B, Phase III, IDA Jeedimetla (V), Quthbullapur (M), Medchal-Malkajgiri District-500 055 Telangana State India@Sy. No. 744, 745, 750, 751, 752 & 753, Mandollagudem Village Choutuppal Mandal, Yadadri District, Telangana, India

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Labetalol Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Labetalol Hydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-09-07

    Pay. Date : 2023-07-26

    DMF Number : 37306

    Submission : 2022-08-09

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-315 - Rev 00

    Issue Date : 2024-08-23

    Type : Chemical

    Substance Number : 923

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2023-05-15

    Valid Till : 2026-05-14

    Written Confirmation Number : WC-0558

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 82245-0203

    Start Marketing Date : 1987-04-06

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Levocetirizine Dihydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Levocetirizine Dihydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-06-02

    Pay. Date : 2017-04-27

    DMF Number : 22286

    Submission : 2008-12-15

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2024-050 - Rev 00

    Issue Date : 2024-08-26

    Type : Chemical

    Substance Number : 3115

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-11-28

    Valid Till : 2025-09-08

    Written Confirmation Number : WC-0072

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0108

    Start Marketing Date : 2008-01-28

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Meclizine Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Meclizine Hydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-10-01

    Pay. Date : 2015-09-21

    DMF Number : 25418

    Submission : 2011-10-25

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2015-242 - Rev 00

    Issue Date : 2021-09-10

    Type : Chemical

    Substance Number : 622

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-11-28

    Valid Till : 2025-09-08

    Written Confirmation Number : WC-0072

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0114

    Start Marketing Date : 1982-01-20

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Rivaroxaban

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Rivaroxaban

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-04-21

    Pay. Date : 2014-12-11

    DMF Number : 28807

    Submission : 2014-11-06

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2021-091 - Rev 01

    Issue Date : 2024-10-04

    Type : Chemical

    Substance Number : 2932

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-10-17

    Valid Till : 2025-08-08

    Written Confirmation Number : WC-0382

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66022-0203

    Start Marketing Date : 2011-07-01

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Lee Sung International Co., Ltd.

    Registration Date : 2020-07-07

    Registration Number : Thu21-11-ND

    Manufacturer Name : Symed Labs Ltd(Unit-I)

    Manufacturer Address : Sy. No. 353, Domadugu Village Gummadidala (Mandal), Sangreddy District Telangana State, India

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Sertraline Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Specialty & Agro Chemical
    Not Confirmed
    arrow

    Sertraline Hydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Specialty & Agro Chemical
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2024-02-12

    Pay. Date : 2024-01-09

    DMF Number : 38163

    Submission : 2023-03-16

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-462 - Rev 00

    Issue Date : 2024-07-25

    Type : Chemical

    Substance Number : 1705

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-10-21

    Valid Till : 2025-09-11

    Written Confirmation Number : WC-0451

    Address of the Firm :

    NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Viyash Life Sciences and get a quotation

    Viyash Life Sciences is a supplier offers 133 products (APIs, Excipients or Intermediates).

    Find a price of Labetalol Hydrochloride bulk with DMF, CEP, WC offered by Viyash Life Sciences

    Find a price of Lacosamide bulk with DMF, CEP, WC offered by Viyash Life Sciences

    Find a price of Bosentan Hydrate bulk with JDMF, WC offered by Viyash Life Sciences

    Find a price of Dolutegravir Sodium bulk with DMF, WC offered by Viyash Life Sciences

    Find a price of Lamivudine bulk with DMF, WC offered by Viyash Life Sciences

    Find a price of Losartan Potassium bulk with DMF, CEP offered by Viyash Life Sciences

    Find a price of Rivastigmine bulk with JDMF, WC offered by Viyash Life Sciences

    Find a price of Tenofovir Disoproxil Fumarate bulk with DMF, WC offered by Viyash Life Sciences

    Find a price of Ticagrelor bulk with DMF, CEP offered by Viyash Life Sciences

    Find a price of Apixaban bulk with DMF offered by Viyash Life Sciences

    Find a price of Baclofen bulk with DMF offered by Viyash Life Sciences

    Find a price of Clomiphene Citrate bulk with DMF offered by Viyash Life Sciences

    Find a price of Dapagliflozin Propanediol Monohydrate bulk with DMF offered by Viyash Life Sciences

    Find a price of Dimethyl Fumarate bulk with WC offered by Viyash Life Sciences

    Find a price of Epinephrine Bitartrate bulk with JDMF offered by Viyash Life Sciences

    Find a price of Febuxostat bulk with WC offered by Viyash Life Sciences

    Find a price of Fingolimod Hydrochloride bulk with WC offered by Viyash Life Sciences

    Find a price of Glycopyrronium Bromide bulk with DMF offered by Viyash Life Sciences

    Find a price of Lenalidomide bulk with WC offered by Viyash Life Sciences

    Find a price of Letrozole bulk with JDMF offered by Viyash Life Sciences

    Find a price of Linagliptin bulk with DMF offered by Viyash Life Sciences

    Find a price of Mavacamten bulk with DMF offered by Viyash Life Sciences

    Find a price of Olmesartan Medoxomil bulk with DMF offered by Viyash Life Sciences

    Find a price of Palbociclib bulk with WC offered by Viyash Life Sciences

    Find a price of Pomalidomide bulk with WC offered by Viyash Life Sciences

    Find a price of Pramipexole Dihydrochloride bulk with WC offered by Viyash Life Sciences

    Find a price of Proguanil bulk with WC offered by Viyash Life Sciences

    Find a price of Sertraline Hydrochloride bulk with CEP offered by Viyash Life Sciences

    Find a price of Vilazodone Hydrochloride bulk with DMF offered by Viyash Life Sciences

    Find a price of Viloxazine Hydrochloride bulk with DMF offered by Viyash Life Sciences

    Find a price of Vonoprazan Fumarate bulk with DMF offered by Viyash Life Sciences

    Find a price of SERTRALINE HYDROCHLORIDE (FORM-II) bulk with DMF offered by Viyash Life Sciences

    Find a price of Abacavir Sulfate bulk offered by Viyash Life Sciences

    Find a price of Abemaciclib bulk offered by Viyash Life Sciences

    Find a price of Ademetionine bulk offered by Viyash Life Sciences

    Find a price of Agomelatine bulk offered by Viyash Life Sciences

    Find a price of Alectinib Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Alpelisib bulk offered by Viyash Life Sciences

    Find a price of Amisulpride bulk offered by Viyash Life Sciences

    Find a price of Apalutamide bulk offered by Viyash Life Sciences

    Find a price of Avapritinib bulk offered by Viyash Life Sciences

    Find a price of Bilastine bulk offered by Viyash Life Sciences

    Find a price of Bosentan Hydrate bulk offered by Viyash Life Sciences

    Find a price of Brimonidine Tartrate bulk offered by Viyash Life Sciences

    Find a price of Carbinoxamine bulk offered by Viyash Life Sciences

    Find a price of Carvedilol bulk offered by Viyash Life Sciences

    Find a price of Carvedilol Phosphate bulk offered by Viyash Life Sciences

    Find a price of Cinitapride Hydrogen Tartrate bulk offered by Viyash Life Sciences

    Find a price of Dabrafenib Mesylate bulk offered by Viyash Life Sciences

    Find a price of Dapoxetine Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Deferasirox bulk offered by Viyash Life Sciences

    Find a price of Edoxaban Tosylate bulk offered by Viyash Life Sciences

    Find a price of Empagliflozin bulk offered by Viyash Life Sciences

    Find a price of Encorafenib bulk offered by Viyash Life Sciences

    Find a price of Epalrestat bulk offered by Viyash Life Sciences

    Find a price of Epinephrine bulk offered by Viyash Life Sciences

    Find a price of Eszopiclone bulk offered by Viyash Life Sciences

    Find a price of Etripamil bulk offered by Viyash Life Sciences

    Find a price of Ezetimibe bulk offered by Viyash Life Sciences

    Find a price of Ferric Carboxymaltose bulk offered by Viyash Life Sciences

    Find a price of Ferric Maltol bulk offered by Viyash Life Sciences

    Find a price of Finerenone bulk offered by Viyash Life Sciences

    Find a price of Fingolimod Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Flibanserin bulk offered by Viyash Life Sciences

    Find a price of Fluorouracil bulk offered by Viyash Life Sciences

    Find a price of Formoterol Fumarate bulk offered by Viyash Life Sciences

    Find a price of Frovatriptan Succinate Hydrate bulk offered by Viyash Life Sciences

    Find a price of Gepotidacin bulk offered by Viyash Life Sciences

    Find a price of Hydroxychloroquine Sulphate bulk offered by Viyash Life Sciences

    Find a price of Hydroxyzine Dihydrochloride bulk offered by Viyash Life Sciences

    Find a price of Hydroxyzine Pamoate bulk offered by Viyash Life Sciences

    Find a price of Idrocilamide bulk offered by Viyash Life Sciences

    Find a price of Iloperidone bulk offered by Viyash Life Sciences

    Find a price of Iptacopan Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Iron III Hydroxide Polymaltose Complex bulk offered by Viyash Life Sciences

    Find a price of Iron Sucrose bulk offered by Viyash Life Sciences

    Find a price of Itopride Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Ivacaftor bulk offered by Viyash Life Sciences

    Find a price of Ketorolac Trometamol bulk offered by Viyash Life Sciences

    Find a price of Lanthanum Carbonate bulk offered by Viyash Life Sciences

    Find a price of Levocetirizine Dihydrochloride bulk offered by Viyash Life Sciences

    Find a price of Levodropropizine bulk offered by Viyash Life Sciences

    Find a price of Levosulpiride bulk offered by Viyash Life Sciences

    Find a price of Linezolid bulk offered by Viyash Life Sciences

    Find a price of Lisdexamfetamine Dimesylate bulk offered by Viyash Life Sciences

    Find a price of Lopinavir bulk offered by Viyash Life Sciences

    Find a price of Macitentan bulk offered by Viyash Life Sciences

    Find a price of Meclizine Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Meprobamate bulk offered by Viyash Life Sciences

    Find a price of Mirdametinib bulk offered by Viyash Life Sciences

    Find a price of Mirogabalin Besylate bulk offered by Viyash Life Sciences

    Find a price of Modafinil bulk offered by Viyash Life Sciences

    Find a price of Mosapride Citrate bulk offered by Viyash Life Sciences

    Find a price of Neratinib bulk offered by Viyash Life Sciences

    Find a price of Obicetrapib bulk offered by Viyash Life Sciences

    Find a price of Olaparib bulk offered by Viyash Life Sciences

    Find a price of Ondansetron Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Osimertinib Mesylate bulk offered by Viyash Life Sciences

    Find a price of Otilonium Bromide bulk offered by Viyash Life Sciences

    Find a price of Phentermine Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Pitolisant Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Prasugrel Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Pregabalin bulk offered by Viyash Life Sciences

    Find a price of Prucalopride Succinate bulk offered by Viyash Life Sciences

    Find a price of Racecadotril bulk offered by Viyash Life Sciences

    Find a price of Rasagiline Mesylate bulk offered by Viyash Life Sciences

    Find a price of Resmetirom bulk offered by Viyash Life Sciences

    Find a price of Ribociclib bulk offered by Viyash Life Sciences

    Find a price of Ritonavir bulk offered by Viyash Life Sciences

    Find a price of Rivaroxaban bulk offered by Viyash Life Sciences

    Find a price of Roflumilast bulk offered by Viyash Life Sciences

    Find a price of Rotigotine bulk offered by Viyash Life Sciences

    Find a price of Ruxolitinib Phosphate bulk offered by Viyash Life Sciences

    Find a price of Saxagliptin Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Seladelpar Lysine bulk offered by Viyash Life Sciences

    Find a price of Selexipag bulk offered by Viyash Life Sciences

    Find a price of Selpercatinib bulk offered by Viyash Life Sciences

    Find a price of Sodium Zirconium Cyclosilicate bulk offered by Viyash Life Sciences

    Find a price of Sparsentan bulk offered by Viyash Life Sciences

    Find a price of Tamsulosin bulk offered by Viyash Life Sciences

    Find a price of Tapentadol bulk offered by Viyash Life Sciences

    Find a price of Tapentadol Phosphate bulk offered by Viyash Life Sciences

    Find a price of Thalidomide bulk offered by Viyash Life Sciences

    Find a price of Tizanidine Hydrochloride bulk offered by Viyash Life Sciences

    Find a price of Tofisopam bulk offered by Viyash Life Sciences

    Find a price of Trofinetide bulk offered by Viyash Life Sciences

    Find a price of Tucatinib bulk offered by Viyash Life Sciences

    Find a price of Venetoclax bulk offered by Viyash Life Sciences

    Find a price of Vibegron bulk offered by Viyash Life Sciences

    Find a price of Vilazodone bulk offered by Viyash Life Sciences

    Find a price of Vismodegib bulk offered by Viyash Life Sciences

    Find a price of Vortioxetine Hydrobromide bulk offered by Viyash Life Sciences

    Find a price of Xanomeline bulk offered by Viyash Life Sciences

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search